Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.

ABSTRACT:

Background

Biomarkers based on detecting prostate cancer (PCa)-specific transcripts in blood are associated with inferior outcomes, but their validation in a clinical context is lacking.

Objective

To determine whether detecting enhanced transcripts for PCa in whole blood using an analytically valid assay has prognostic significance relative to circulating tumor cell (CTC) enumeration.

Design, setting, and participants

The detection of KLK3, KLK2, HOXB13, GRHL2, and FOXA1 in whole blood by reverse transcription polymerase chain reaction (RT-PCR) was studied in 97 men with metastatic castration-resistant PCa (mCRPC) as a prognostic factor for overall survival.

Intervention

The 2.5 ml of blood was collected in PAXgene tubes for total RNA extraction and 7.5 ml for

SUBMITTER: Danila DC 

PROVIDER: S-EPMC4113474 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature